GlobeNewswire by notified

Anoto publishes its annual report for 2023 and corrects for changes in the results as reported in the year-end report

Share

Stockholm, 30 April 2024 - Anoto Group AB (publ) (“Anoto”) today publishes its annual report for 2023 and corrects for changes in the results as reported in the year-end report published on 29 February 2024. The annual report is available on the Company’s website, www.anoto.com.

Compared to previously communicated results in the year-end report for 2023, Anoto reports a change in the results in the annual report. The corrections on the consolidated results stemmed from updates made to the Group’s impairment testing and financial forecasts, and relate to write-downs of goodwill, capitalized costs, and investment in Knowledge AI Inc., a former subsidiary and currently associated company of Anoto. The Group has written down 59.3 MSEK of goodwill in Livescribe Inc., and fully impaired its remaining goodwill in Anoto Korea – 37.6 MSEK. In addition, the Group has fully impaired its remaining fair value investment of 38.4 MSEK in Knowledge AI Inc. and 13.6 MSEK of its loan receivables. Finally, the Group has also fully impaired its capitalized R&D related to Knowledge AI Inc., totaling 2.8 MSEK and an additional 2.6 MSEK of capitalized R&D for a product nearing its end of life. All impairments had a negative impact on the Group’s consolidated results, with a total effect of 154.3 MSEK. The Group’s results for 2023 amounts to MSEK -84.2 compared to what was reported in the year-end report, 70.1 MSEK, and earnings per share amounts to -0.25 SEK compared to 0.29 SEK. The figures have been updated in the annual report for 2023.

The Group also reports a minor change in the results of the parent company. The corrections on the parent company results are related to a write-down of participation and loan receivables in subsidiaries. As a result of updated impairment testing done on subsidiaries, the parent company has written down 6.2 MSEK on the value of the parent company’s participation in Anoto Korea and 2.1 MSEK in Anoto AB. In addition, the parent company has written down a total of 64.1 MSEK in loan receivables, 28.6 MSEK from Anoto Korea, 7.3 MSEK from Anoto Singapore, 27.7 MSEK from Anoto Inc., and 0.4 MSEK from Anoto Portugal. These corrections have also been updated in the annual report for 2023, with no impact on the Group’s consolidated results.

For further information contact:

Kevin Adeson, Chairman of the Board of Directors

For more information about Anoto, visit www.anoto.com or email ir@anoto.com

Anoto Group AB (publ), Reg.No. 556532-3929, Flaggan 1165, 116 74 Stockholm

This information constitutes inside information as Anoto Group AB (publ) is obliged to disclose under the EU Market Abuse Regulation 596/2014. The information was provided by the contact person above for publication on 30 April 2024 at 23:30 CEST.

About Anoto Group

Anoto is a publicly held Swedish technology company known globally for innovation in the area of information-rich patterns and the optical recognition of those patterns. It is a leader in digital writing and drawing solutions, having historically used its proprietary technology to develop smartpens and related software. These smartpens enrich the daily lives of millions of people around the world. Anoto currently has two main business lines: Retail Products and Enterprise Solutions & Licensing. Anoto also holds a stake in Knowledge AI, a leading AI based education solution company. Anoto is traded on the Small Cap list of Nasdaq Stockholm under ANOT.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Disclosure of shareholding in IDEX Biometrics - 21 May 202421.5.2024 23:30:00 CEST | Press release

This notice is issued by IDEX Biometrics ASA on behalf of the shareholder mentioned below. IDEX Biometrics ASA disclosed on 15 May 2024 that it had conducted a private placement of 33.3 million new shares in IDEX Biometrics. Tranche 1 of the private placement amounted to 27.9 million shares. In connection with the private placement, the managers of the private placement, IDEX Biometrics and certain existing shareholders entered into a share lending agreement. Mr. Robert Keith participated in the private placement and subscribed for 3,619,380 shares in Tranche 1. Mr. Keith has also lent 17,940,213 shares in connection with the settlement of the private placement. The shares have been lent, not sold, and will be returned in due course. After the temporary disposal of shares, Mr. Keith and close relations hold 16,770,266 shares or rights to shares or 5.4% of the total outstanding shares and votes in IDEX Biometrics after completion of Tranche 1. For further information contact: Marianne B

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram samt ophør af aktietilbagekøbsprogram21.5.2024 23:25:36 CEST | pressemeddelelse

KØBENHAVN, Danmark, 21. maj 2024 – Bavarian Nordic A/S (OMX: BAVA) meddeler, at aktietilbagekøbsprogrammet, der blev offentliggjort og iværksat den 8. maj 2024, nu er afsluttet, da det planlagte antal aktier er tilbagekøbt. Programmet blev gennemført i overensstemmelse med bestemmelserne i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april 2014 om markedsmisbrug og supplerende forordning (EU) nr. 2016/1052 af 8. marts 2016, der samlet udgør Safe Harbour-lovgivningen. Formålet med programmet var at opfylde selskabets forpligtelser i henhold til det aktiebaserede incitamentsprogram for bestyrelsen og direktionen. Under aktietilbagekøbsprogrammet har Bavarian Nordic A/S tilbagekøbt 162.288 aktier jf. tabellen nedenfor. TransaktionsdatoAntal aktierGennemsnitlig købspris, DKKTransaktionsværdi, DKK8. maj 202425.000158,743.968.50013. maj 202425.000163,934.098.25014. maj 202425.000167,744.193.50015. maj 202435.000169,765.941.60016. maj 202415.000173,862.607.90017. maj 2024

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program21.5.2024 23:25:36 CEST | Press release

COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on May 8, 2024, has now been terminated, as the intended number of shares under the program has been repurchased. The program was executed in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and supplementing Regulation (EU) 2016/1052 of 8 March 2016, which together constitute the Safe Harbour Regulation. The purpose of the program was to meet the Company’s obligations arising from the share-based incentive program for the Board of Directors and Executive Management. Under the program Bavarian Nordic A/S has bought back 162,288 shares, cf. the table below: Transaction dateNumber of sharesAverage purchase price, DKKTransaction Value, DKKMay 8, 202425,000158.743,968,500May 13, 202425,000163.934,098,250May 14, 202425,000167.744,193,500May 15, 202435,00016

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update21.5.2024 23:14:00 CEST | Press release

Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech signed new commercialization agreements for its high concentration interchangeable biosimilar to Humira® in the U.S. and for its proposed biosimilar to Prolia® and Xgeva® in the U.S. and Europe. Alvotech raises topline revenue guidance to $400-$500 million and tightens guidance for bottom line range for 2024 to $100-$150 million. Management will conduct a business update conference call and live webcast on Wednesday May 22, 2024, at 8:00 am ET (12:00 pm GMT) Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of 2024 and provided a summary of recent corporate highlights. “This year is turning o

Atico Reports Consolidated Financial Results for First Quarter of 202421.5.2024 22:30:00 CEST | Press release

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the three months ended March 31, 2024, posting income from mining operations of $2.8 million and a net loss of $0.4 million. Production for the period at Atico’s El Roble mine totaled 3.3 million pounds (“lbs”) of copper and 2,185 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.57 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, "the operational and financial results for this quarter were in line with Company expectations. We are already into development of the newly discovered reserves and have been making additional investments in preparation for ore extraction from these areas.” Mr. Ganoza continued, “for the remainder of the year, we should start to see an improvement in our operating costs as we

HiddenA line styled icon from Orion Icon Library.Eye